LOW-DOSE CYCLOSPORINE-A THERAPY IN BEHCETS-DISEASE

被引：28

作者：

SAJJADI, H

SOHEILIAN, M

AHMADIEH, H

HASSANEIN, K

PARVIN, M

AZARMINA, M

EHYAEE, V

AMIRANSARI, B

机构：

[1] Department of Ophthalmology, Kansas University Medical Center, Kansas City, Kansas

[2] Department of Ophthalmology, Shaheed Beheshti University, Tehran

[3] Department of Biometry, Kansas University Medical Center, Kansas City, Kansas

[4] Department of Nephrology-Internal Medicine, Shaheed Beheshti University, Tehran

来源：

JOURNAL OF OCULAR PHARMACOLOGY | 1994年 / 10卷 / 03期

关键词：

D O I：

10.1089/jop.1994.10.553

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The effect of systemic low dose cyclosporin-A (5 mg/kg/day as initial dose) combined with 0.2 to 0.6 mg/kg/day prednisolone (when necessary) in clinical course of 22 patients suffering from severe forms of Behcet's disease are reviewed. All the patients had received other drugs previously and had either no response to them or developed intolerable side effects, therefore, pre treatment visual acuity (VA) was compared to post treatment VA as ''self control''. The average age of our patients was 30.6 years (range 19-51 years). The average duration of our therapy was 19.5 months (range 4-32 months). Improvement or stabilization of vision was achieved in 21 patients (95%). The intraocular inflammation was controlled in all of the eyes and most of the non-ocular signs and symptoms were also improved. Serious side effects included rise in creatinine in 10 (45%) of the patients, rise in bilirubin in 6 (27%) and hypertension in 1 (4.5%). These side effects disappeared as the dose of cyclosporin-A was tapered. We believe this form of therapy is of great value in the management of severe forms of Behcet's disease.

引用

页码：553 / 560

页数：8

共 23 条

[1]

Kasp E., Graham E.M., Stanford M.R., Sanders M.D., Dulmonde D.C., A point prevalence study of 150 patients with idiopathic retinal vasculitis: clinical relevance of antiretinal autoimmunity and circulating immune complexes, Br. J. Ophthalmol., 73, (1989)

[2]

Capers L.E., Velu G.D., Libert J., Cyclosporine in Behcet's disease: Resistant to conventional therapy, Ann. Ophthalmol, 21, (1989)

[3]

Nussenblatt R.B., Palestine A.G., pp. 212-232, (1989)

[4]

Katzung B.G., Basic and Clinical Pharmacology, (1992)

[5]

Ben Ezra D., Nussenblatt R.B., Timonen P., Optimal use of Sandimmun in endogenous uveitis, pp. 1-22, (1988)

[6]

Hogan M.H., Kimura S.I., Thygeson P., Signs and symptoms of uveitis in anterior uveitis, Am. I. Ophthalmol., 67, (1959)

[7]

Binder A.I., Graham E.M., Sanders M.D., Dinning W., Lames D.G., Denman A.M., Cyclosporin-A in the treatment of severe Behcet's uveitis, Br. J. Ophthalmol., 26, (1987)

[8]

Nussenblatt R.B., Kuwabara T., Demonasterio F.N., Wacker N.B., S-Antigen uveitis in primates: A new model for human disease, Arch. Ophthalmo1., 104, (1986)

[9]

Hirose S., Kuwabara T., Nussenblatt R.B., Wiggert B., Redmond T.M., Iery I., Uveitis induced in primates by interphotoreceptor retinoid binding protein, Arch. Ophthalmol., 104, (1986)

[10]

Karin S., Froebel S., Armstrong S., Cliffe M., Urbaniak S.I., Forrester I.V., An investigation of the general immune status and specific immune responsiveness to retinal (S) antigen in patients with chronic posterior uveitis, Eye., 3, (1989)

← 1 2 3 →